nach oben

Drugs

Erschienen in:

01.08.2008 | Adis Drug Profile

Dabigatran Etexilate

verfasst von: Mark Sanford, Greg L. Plosker

Erschienen in: Drugs | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

▲ Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation.
▲ Dabigatran etexilate pharmacokinetics were linear across a wide dosage range. There were no clinically important pharmacokinetic interactions with digoxin (a P-glycoprotein substrate), pantoprazole (a proton-pump inhibitor) or drugs that are substrates and/or inhibitors of hepatic cytochrome P450 enzymes.
▲ In two large, randomized, double-blind trials of the prevention of venous thromboembolism (VTE) in patients undergoing total hip or total knee replacement surgery, orally administered dabigatran etexilate 220 mg/day was noninferior to subcutaneous enoxaparin sodium 40 mg/day for the primary composite endpoint of total VTE events or all-cause mortality during the treatment period.
▲ There were no significant differences between dabigatran etexilate and enoxaparin sodium in major VTE events and VTE-related mortality. Across trials, ≤0.5% of patients experienced a symptomatic pulmonary embolus or died.
▲ Dabigatran etexilate was generally well tolerated. In patients undergoing total hip or total knee replacement surgery, there was no significant difference between dabigatran etexilate and enoxaparin sodium recipients in the incidence of major or minor bleeding.

The use of trade names is for identification purposes only and does not imply endorsement.

National Collaborating Centre for Acute Care. National Institute for Health and Clinical Excellence clinical guideline 46: venous thromboembolism. Reducing the risk of venous thrombo-embolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery [online]. Available from URL: http://www.nice.org.uk/Guidance/CG46 [Accessed 2008 May 13]

Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs 2004; 64(6): 577–95PubMedCrossRef

Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 Suppl. 3: 265–86sCrossRef

Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 Suppl. 3: 3338–4005sCrossRef

Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005 Aug; 3(8): 1843–53PubMedCrossRef

Boehringer Ingelheim Limited. Pradaxa: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2008 May 15]

Wienen W, Stassen J-M, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007 Jul; 98(1): 155–62PubMed

van Ryn J, Hauel N, Waldmann L, et al. Dabigatran inhibits both clot-bound and fluid phase thrombin in vitro: effects compared to heparin and hirudin [abstract no. 3998]. Blood 2007; 110(11): 68B

van Ryn J, Kink-Eiband M, Hauel N et al. Effects of dabigatran, a direct thrombin inhibitor, as compared to the direct factor Xa inhibitors, rivaroxaban and apixaban, on tissue factor-induced human platelet aggregation in platelet rich plasma [abstract no. 1884]. Blood 2007; 110(11): 558a. Plus poster presented at the 49th Meeting of the American Society of Hematology; 2007 Dec 8–11; Atlanta (GA)

10.

Liesenfeld K-H, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62(5): 527–37PubMedCrossRef

11.

Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 Sep; 64(3): 292–303PubMedCrossRef

12.

Stangier J, Stahle H, Rathgen K. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008 Jan; 47(1): 47–59PubMedCrossRef

13.

Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47(5): 285–95PubMedCrossRef

14.

Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004 Sep; 2(9): 1573–80PubMedCrossRef

15.

Stangier J, Eriksson BI, Dahl OE. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45(5): 555–63PubMedCrossRef

16.

Stangier J, Rathgen K, Stahle H, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate in subjects with moderate hepatic impairment [abstract no. P-W-673]. J Thromb Haemost 2007 Aug 6; 5 Suppl. 2

17.

Troconiz IF, Tillmann C, Liesenfeld KH, et al. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007 Mar; 47(3): 371–82PubMedCrossRef

18.

Stangier J, Stahle H, Rathgen K. Effect of food and pantoprazole on the bioavailability of the direct thrombin inhibitor dabigatran in healthy subjects [abstract no.1612]. J Thromb Haemost 2005; 3 Suppl. 1

19.

Eriksson BI, Dahl OE, Rosencher N. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 Sep 15; 370(9591): 949–56PubMedCrossRef

20.

Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 Nov; 5(11): 2178–85PubMedCrossRef

21.

The RE-MOBILIZE writing committee. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. Epub 2008 Apr 14

22.

European Medicines Agency. CHMP assessment report for Pradaxa. London: European Medicines Agency, 2008; EMEA/174363/2008: 36

23.

Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005 Jan; 3(1): 103–11PubMedCrossRef

24.

UK Department of Health. Report of the independent expert working group on the prevention of venous thromboembolism in hospitalised patients [online]. Available from URL: http://www.thrombosis-charity.org.uk/cms/images/stories/File/reports/Report%20of%20the%20Expert%20Group%202007.pdf [Accessed 2008 Jun 26]

Titel: Dabigatran Etexilate
verfasst von: Mark Sanford
Greg L. Plosker
Publikationsdatum: 01.08.2008
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868120-00007

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Dabigatran Etexilate

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2008

Promising Newer Molecular-Targeted Therapies in Head and Neck Cancer

Cevimeline

Managing the Patient with Co-Morbid Depression and an Anxiety Disorder

Fentanyl Transdermal Matrix Patch (Durotep® MT Patch; Durogesic® DTrans®; Durogesic® SMAT)

Ciclesonide

Endothelin Receptor Antagonism